A New Way To Fight Head Lice.
Insecticide-treated underwear won't wipe out lice infestations in dispossessed shelters, according to a additional study. The design initially showed some success, but the lice soon developed resistance to the chemical, the researchers said. Body lice can limits through direct contact and shared clothing and bedding, and the problem is worsened by overcrowded conditions.
Showing posts with label received. Show all posts
Showing posts with label received. Show all posts
Tuesday, 21 November 2017
Friday, 17 February 2017
Vaccination Against Tuberculosis Prevents Multiple Sclerosis
Vaccination Against Tuberculosis Prevents Multiple Sclerosis.
A vaccine normally worn to short-circuit the respiratory illness tuberculosis also might help prevent the development of multiple sclerosis, a blight of the central nervous system, a new study suggests Dec 2013. In grass roots who had a first episode of symptoms that indicated they might develop multiple sclerosis (MS), an injection of the tuberculosis vaccine lowered the probability of developing MS, Italian researchers report. "It is feasible that a safe, handy and cheap approach will be available immediately following the first episode of symptoms suggesting MS," said studio lead author Dr Giovanni Ristori, of the Center for Experimental Neurological Therapies at Sant'Andrea Hospital in Rome.
But, the swat authors cautioned that much more scrutiny is needed before the tuberculosis vaccine could possibly be used against multiple sclerosis. In people with MS, the unaffected system attacks healthy cells in the central nervous system, which includes the perspicacity and spinal cord. One of the first signs of MS is what's known as "clinically secluded syndrome". Symptoms include numbing and problems with vision, hearing and balance.
About half of relations who experience clinically isolated syndrome develop MS within two years. The study, published online Dec. 4 in the log Neurology, included 73 people who'd had clinically lonely syndrome. Thirty-three received the tuberculosis vaccine and the remaining 40 were given a placebo, or dummy, injection. The tuberculosis vaccine is a active vaccine called the Bacille Calmette-Guerin vaccine, which isn't extensively used in the United States.
The same vaccine also is being studied as a treatment for specimen 1 diabetes. The participants had monthly MRI scans of their brains for the first six months of the review to look for lesions associated with multiple sclerosis. For the next year, they received a narcotize (interferon beta-1a) given to people with MS. After that, they received the treatment recommended by their own neurologist. After five years, the participants were reexamined to glom if they had developed MS.
A vaccine normally worn to short-circuit the respiratory illness tuberculosis also might help prevent the development of multiple sclerosis, a blight of the central nervous system, a new study suggests Dec 2013. In grass roots who had a first episode of symptoms that indicated they might develop multiple sclerosis (MS), an injection of the tuberculosis vaccine lowered the probability of developing MS, Italian researchers report. "It is feasible that a safe, handy and cheap approach will be available immediately following the first episode of symptoms suggesting MS," said studio lead author Dr Giovanni Ristori, of the Center for Experimental Neurological Therapies at Sant'Andrea Hospital in Rome.
But, the swat authors cautioned that much more scrutiny is needed before the tuberculosis vaccine could possibly be used against multiple sclerosis. In people with MS, the unaffected system attacks healthy cells in the central nervous system, which includes the perspicacity and spinal cord. One of the first signs of MS is what's known as "clinically secluded syndrome". Symptoms include numbing and problems with vision, hearing and balance.
About half of relations who experience clinically isolated syndrome develop MS within two years. The study, published online Dec. 4 in the log Neurology, included 73 people who'd had clinically lonely syndrome. Thirty-three received the tuberculosis vaccine and the remaining 40 were given a placebo, or dummy, injection. The tuberculosis vaccine is a active vaccine called the Bacille Calmette-Guerin vaccine, which isn't extensively used in the United States.
The same vaccine also is being studied as a treatment for specimen 1 diabetes. The participants had monthly MRI scans of their brains for the first six months of the review to look for lesions associated with multiple sclerosis. For the next year, they received a narcotize (interferon beta-1a) given to people with MS. After that, they received the treatment recommended by their own neurologist. After five years, the participants were reexamined to glom if they had developed MS.
Sunday, 10 April 2016
Anesthesia Affects The Heart
Anesthesia Affects The Heart.
More unsettle about the safety of a common anesthetic has been raised in a unripe study. Patients who received the anesthesia drug etomidate during surgery might be at increased chance for cardiovascular problems or death, according to the study, which was published in the December issue of the journal Anesthesia and Analgesia. An accompanying column in the journal said the findings add to growing concerns about the use of the drug. The survey compared about 2100 patients who received etomidate and about 5200 patients who received another intravenous anesthetic called propofol.
All of the patients in the deliberate over underwent surgery that didn't number among the heart. Compared to those who received propofol, patients who received etomidate had a significantly higher gamble of death within 30 days after surgery, according to a journal news release. The risk was 6,5 percent in the etomidate organize and 2,5 percent in the propofol group, said study chief Dr Ryu Komatsu, of the Cleveland Clinic in Ohio.
More unsettle about the safety of a common anesthetic has been raised in a unripe study. Patients who received the anesthesia drug etomidate during surgery might be at increased chance for cardiovascular problems or death, according to the study, which was published in the December issue of the journal Anesthesia and Analgesia. An accompanying column in the journal said the findings add to growing concerns about the use of the drug. The survey compared about 2100 patients who received etomidate and about 5200 patients who received another intravenous anesthetic called propofol.
All of the patients in the deliberate over underwent surgery that didn't number among the heart. Compared to those who received propofol, patients who received etomidate had a significantly higher gamble of death within 30 days after surgery, according to a journal news release. The risk was 6,5 percent in the etomidate organize and 2,5 percent in the propofol group, said study chief Dr Ryu Komatsu, of the Cleveland Clinic in Ohio.
Subscribe to:
Posts (Atom)